FDA Approval Alert: The Need-to-Know | Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRC

In January 2023, the FDA has given tucatinib in combination with trastuzumab accelerated approval by the FDA for the treatment of patients with RAS wild-type, HER2-positive metastatic colorectal cancer who have received at least 1 line of treatment for unresectable or metastatic disease.

An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.
FDA Accelerated Approval of Tucatinib/Trastuzumab for HER2+ Metastatic CRC May ‘Improve Access’ to Treatment
Video
Jan 20, 2023 5:00 PM
An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.
FDA Grants Accelerated Approval to Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRC
Article
Jan 19, 2023 8:21 PM
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.